Virtual Conference
Pharma Conference 2022

Tolkacheva D.G

Russian Presidential Academy of National Economy and Public Administration, Russian Federation

Title: Treatment of moderate-to-severe active psoriatic arthritis: cost-effectiveness analysis and budget impact analysis of biologics and targeted therapies approved in the Russian Federation


Background: Although the development of biologics has opened new horizons for the treatment of moderate-to-severe active psoriatic arthritis (PsA), these drugs present a large financial burden for payers. 

Objective: To perform cost-effectiveness analysis (CEA) and budget impact analysis (BIA) of netakimab in comparison with other biologics (adalimumab, golimumab, guselkumab, ixekizumab, infliximab, secukinumab, ustekinumab, certolizumab pegol, etanercept) and targeted therapies (apremilast, tofacitinib) in adults with PsA.

Materials: CEA and BIA were carried out from the Russian healthcare system perspective. Comparative effectiveness of the drugs was derived from the network meta-analysis. Results of indirect comparisons based on ACR20, ACR50, ACR70, PASI 75, and PASI 90 were converted into quality-adjusted life years (QALYs) and then used in CEA. We compared only the direct medical costs of the drugs assuming they have a comparable safety profile. If biosimilars were approved and available on the market, we used the median of registered prices to calculate the annual costs. For BIA we calculated the difference in costs of PsA treatment between the current prescription practice and the case of higher netakimab penetration rate. The time horizon for CEA was 2 years, for BIA - 3 years.

Results: Netakimab was the most cost effective treatment option with a CER of 1.2 million rubles per QALY gained. BIA showed that expanded use of netakimab in adults with active PsA will reduce healthcare costs by 377 million rubles or 21.1% in comparison with present clinical practice. It would allow to treat 26.7% more patients in 3 years’ time while not exceeding the current budget.

Conclusions: Netakimab was characterised by higher or similar comparative effectiveness and lower direct costs compared with other biologics and targeted therapies for the treatment of PsA. Expanding netakimab use in clinical practice will substantially decrease the economic burden of PsA on the Russian healthcare system.


Daria Tolkacheva has completed her degree at Saint Petersburg State University, Russia. She is a head of health technology assessment at JSC BIOCAD. She manages a team of three professionals, responsible for HTA at every product lifecycle stage: starting from pipeline management and evaluation in drug development to analysis of clinical development programm, pricing, reimbursement dossier preparation and submission, further evidence synthesis and conducting pharmacoeconomics studies at commercialization.